Skip to Content
Merck
CN
  • Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

JAMA psychiatry (2014-10-02)
Glenn T Konopaske, Nicholas Lange, Joseph T Coyle, Francine M Benes
ABSTRACT

Prior studies have demonstrated reduced dendritic spine density in the dorsolateral prefrontal cortex (DLPFC) in schizophrenia. However, it remains unclear how generalizable this finding is in schizophrenia and if it is seen in bipolar disorder, a historically distinct psychiatric condition. To assess whether spine loss is present in the DLPFC of individuals with schizophrenia and individuals with bipolar disorder. This study used postmortem human brain tissue from individuals with schizophrenia (n=14), individuals with bipolar disorder (n=9), and unaffected control participants (n=19). Tissue samples containing the DLPFC (Brodmann area 46) were Golgi-stained, and basilar dendrites of pyramidal cells in the deep half of layer III were reconstructed. The number of spines per dendrite, spine density, and dendrite length were compared across groups. We also assessed for the potential effects of clinical and demographic variables on dendritic parameters. The mean (SD) spine density was significantly reduced (ie, by 10.5%) in individuals with bipolar disorder (0.28 [0.04] spines/μm) compared with control participants (0.31 [0.05] spines/μm) (P=.02). In individuals with schizophrenia, the mean (SD) spine density was also reduced (by 6.5%; 0.29 [0.03] spines/μm) but just missed significance when compared with control participants (P=.06). There was a significant reduction in the mean (SD) number of spines per dendrite in both individuals with schizophrenia (72.8 [24.9] spines per dendrite) and individuals with bipolar disorder (68.9 [12.9] spines per dendrite) compared with controls (92.8 [31.1] spines per dendrite) (individuals with schizophrenia vs controls: 21.6% reduction [P=.003]; individuals with bipolar disorder vs controls: 25.8% reduction [P=.005]). In addition, both individuals with schizophrenia and individuals with bipolar disorder had a reduced mean (SD) dendrite length (246.5 [67.4] and 245.6 [29.8] μm, respectively) compared with controls (301.8 [75.1] μm) (individuals with schizophrenia vs controls: 18.3% reduction [P=.005]; individuals with bipolar disorder vs controls: 18.6% reduction [P=.005]). Dendritic spine loss in the DLPFC was seen in both individuals with schizophrenia and individuals with bipolar disorder, suggesting that the 2 disorders may share some common pathophysiological features.

MATERIALS
Product Number
Brand
Product Description

Haloperidol, European Pharmacopoeia (EP) Reference Standard
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethanol Fixative 80% v/v, suitable for fixing solution (blood films)
Supelco
Ethanol standards 10% (v/v), 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
Clozapine
Supelco
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Haloperidol, powder
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
USP
Haloperidol, United States Pharmacopeia (USP) Reference Standard
USP
Clozapine, United States Pharmacopeia (USP) Reference Standard
Clozapine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethyl alcohol, Pure 190 proof, for molecular biology
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
Ethanol, tested according to Ph. Eur.
Sigma-Aldrich
o-Xylene, anhydrous, 97%
Supelco
o-Xylene, analytical standard
Supelco
Ethanol, standard for GC
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, meets USP testing specifications
Clozapine for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethanol, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
o-Xylene, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
Ethyl alcohol, Pure, 160 proof, Excise Tax-free, Permit for use required
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
o-Xylene, reagent grade, ≥98.0%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, ≥99.5%